AstraZeneca has announced the unveiling of its newly expanded, state-of-the-art manufacturing facility in Coppell, Texas.
The expansion project will double the production of Lokelma, benefitting patients in the United States and around the world.
The investment of $445m to expand the facility follows the groundbreaking last week at AstraZeneca’s manufacturing facility in Albemarle County, Virginia.
Both are part of AstraZeneca’s $50bn investment in US R&D and manufacturing during the next five years that was announced in July 2025.
Jim Fox, Senior Vice President, Americas Supply Operations, AstraZeneca, said: “Our manufacturing facility in Coppell serves as both a critical pillar in global healthcare and has played an important role in supporting the local workforce during the past 10 years."
"The expansion underscores our commitment to patients and support for Texas’ long-term vision for scientific growth and innovation.”
AstraZeneca’s Coppell facility is the sole global manufacturing facility of Lokelma to more than 50 countries, employing more than 250 people.
Through the expansion and development of a new 9000 sqft building, two novel manufacturing lines will be added.
These will be alongside enhancements to support drug substance and drug product laboratory testing, warehousing, additional manufacturing utilities and administrative space.
At an event marking the unveiling of the expanded facility, Learning Undefeated, an AstraZeneca STEM education partner, will also showcase their interactive educational mobile lab Breakout Box: Manufacturing Mission.
Designed to inspire the next generation of STEM leaders by providing an immersive experience for students to explore the world of manufacturing careers, the mobile lab includes everything from welding to data analytics and robotics and will be available to local schools in Texas.